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ABSTRACT
Purpose: Bladder cancer is a common malignancy, and a frequent cause of urological consul­
tation and surgical intervention. Except for smoking and certain occupational exposures, the 
etiology of bladder cancer is largely unknown* Although the majority of patients with bladder 
cancer do not have a family history of transitional cell carcinoma of the urinary tract, the study 
of familial transitional cell carcinoma may lead to knowledge of the pathogenesis of this disease.
Materials and Methods: To evaluate the current understanding of familial transitional cell 
carcinoma, we reviewed the contemporary literature for case reports and epidemiological studies 
about this disease.
Results: Numerous case reports document the clustering of transitional cell carcinoma in 
families, several of which demonstrate an extremely early age at onset of disease, which argues 
in favor of a genetic component to familial transitional cell carcinoma. The results of large 
epidemiological studies also suggest the existence of familial transitional cell carcinoma, and first 
degree relatives appear to have an increased risk for disease by a factor of 2. Familial clustering 
of smoking does not appear to be the cause of this increased risk.
Conclusions: Familial transitional cell carcinoma may be the result of a genetically transmitted 
predisposition to disease, at least in some affected families. Further studies are required to 
identify candidate genes that may be responsible for this form of bladder cancer.
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Bladder cancer is the fourth most common tumor among 
white men in Western Europe and the United States, follow­
ing prostate, lung and colorectal cancer.1-3 In the United 
States the annual age adjusted incidence is 32/100,000 men 
and the lifetime risk of bladder cancer among white men is 
3.6%. The annual age adjusted incidence among white 
women is 8/100,000.4 For undetermined reasons black men 
experience only half the risk of white men, whereas the risk 
for black women is essentially the same as that for white 
women.4 Of bladder cancers 95% are transitional cell tumors.
Overall, bladder cancer constitutes the bulk of urothelial 
transitional cell neoplasms, with upper tract lesions contrib­
uting less than 1 0 % of all tumors arising from the urothelial 
cell surface.5 Numerous epidemiological studies have shown 
that only smoking and certain occupational exposures (for 
example /3-naphthyl amine, benzidine and 4-aminobiphenyl) 
can be considered important environmental risk factors for 
bladder cancer development.6 Similar data are available for 
transitional cell carcinoma in the upper urinary tract, the 
only difference being phenacetin use, which was identified as 
an additional important risk factor.7-11
Although attention has also been paid recently to genetic 
lesions hypothesized to contribute to transitional cell carci­
noma, the role of familial transmission has yet to be com­
pletely explored. Case reports suggest a familial component
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to bladder cancer. In addition, there is strong evidence for an 
increased risk of ureteral and renal pelvic transitional cell 
carcinoma in families with hereditary nonpolyposis colon 
cancer.12*13 We critically review the available data on fam il­
ial clustering of transitional cell carcinoma.
FAMILIAL TRANSITIONAL CELL CARCINOMA OF THE
BLADDER
Thelen and Schaeuble first reported familial clustering of 
transitional cell carcinoma in 1957, when they described 
identical male twins, both smokers, with “benign transitional 
cell papillomas” of the bladder.14 Fraumeni and Thomas re­
ported 4 cases of bladder cancer in  a family of Russian- 
Jewish origin.15 The father was diagnosed with invasive 
bladder cancer at age 54 years, and 3 sons had bladder cancer 
a t ages 57 and 64 years (2  had well differentiated noninva- 
sive papillary tumors and 1 had metastatic squamous cell 
carcinoma). All affected individuals in this kindred were 
heavy smokers but none was employed in a high risk occu­
pation. The mother died of colon adenocarcinoma, In a fol­
io wup study of this family, 2  sons with bladder cancer la ter 
had primary lung cancers,16
Benton and Henderson presented the occupational histo­
ries of 9 individuals with transitional cell carcinoma of the 
bladder diagnosed before age 25 years .17 One patient was a 
19-year-old repairman with exposure to glues and solvents. 
The father, a welder, was diagnosed with transitional cell 
carcinoma of the bladder 1 year before diagnosis in the son. 
Although chance occurrence is a possible explanation in  this 
family, the young age at onset of disease strongly favors a 
hereditary etiology.
Familial bladder transitional cell carcinoma was also re-
8 6 8 FAMILIAL TRANSITIONAL CELL CANCER
ported by McCullough et al in 6  members of a 2 -generation 
family.18 Four affected patients were diagnosed before age 50 
years and 2 before age 40 years. Two of these patients later 
had upper urinary tract transitional cell carcinoma and 5 had 
other tumors (basal cell, stomach, prostate, cervix uteri and 
unknown primary). Other tumors were also diagnosed 
among the nonaffected siblings in this kindred, including 1 
with leukemia at age 2 0  years and 1 w ith breast cancer at age 
40 years. Interestingly, an identical twin of a patient in this 
kindred with transitional cell carcinoma died of melanoma at 
age 63 years. Although 4 individuals with transitional cell 
carcinoma were smokers and 2 had high risk occupations 
(painter and printer), a germline mutation in 1 unaffected 
parent of 3 affected brothers, resulting in a genetic suscepti­
bility for cancer (especially transitional cell carcinoma) 
seems likely in this extraordinary pedigree.
Three interesting case reports appeared in the late 1970s 
and early 1980s.19~21 Lynch et al reported on 3 siblings 
diagnosed with bladder cancer before age 50 years .19 Purtilo 
et al described 13 cases of bladder transitional cell carcinoma 
in 6  unrelated families in M assachusetts .20 The study is 
interesting because 5 of the 6  families were identified from a 
registration of 162 incident cases of bladder cancer, yielding 
a 3% prevalence estimate of familial bladder cancer, and all 
3 affected individuals in 1 family were diagnosed with dis­
ease at young ages (19, 28 and 33 years old, respectively). 
Mahboubi et al reported 3 cases of transitional cell carcinoma 
in a nuclear family.21
Bladder cancer within a familial context is often seen in 
association with carcinomas of nongenitourinary origin. The 
association with retinoblastoma is especially noteworthy, 
Chan and Pratt described the family of an 1 1 -year-old white 
girl with bilateral retinoblastoma and multiple nonradiation 
induced osteosarcomas,22 The mother had unilateral retino­
blastoma. The maternal grandfather and 1 of his brothers 
were diagnosed with bladder transitional cell carcinoma at 
ages 60 and 47 years, respectively. Aherne described a family 
with retinoblastoma and osteosarcoma in which the mother 
of 2 affected children had bladder cancer a t age 40 years .23 
Aherne also summarized 5 other British cases of retinoblas­
toma. The father of 1 patient died of bladder cancer at age 50 
years. Although based on small numbers, subsequent studies 
confirmed the greater risk of bladder cancer among relatives 
of retinoblastoma patients .24- 26 This greater risk appeared to 
be confined to known carriers of the m utated retinoblastoma 
gene.
FAMILIAL TRANSITIONAL CELL CARCINOMA OF THE UPPER
URINARY TRACT
i
There are several cases of familial transitional cell carci­
noma of the upper urinary tract, the rarity of which favors a 
genetic origin. Some of these cases were reported before the 
risk of this tumor was suggested to be great in families with 
hereditary nonpolyposis colon cancer.12 Therefore, it is not 
always possible to evaluate whether familial transitional cell 
carcinomas of the ureter and renal pelvis occur in a site 
specific manner. Burkland and Juzek reported on a 6 8 -year- 
old white woman and her 53-year-old son, both of whom had 
transitional cell carcinoma of the right ureter .27 Her oldest 
sister died of intestinal cancer a t age 60 years, Orphali et al 
described 3 siblings with transitional cell carcinoma of the 
upper urinary tract .28 Another sibling had cervical cancer 
and the father was diagnosed with lymphosarcoma a t a late 
age. Three paternal uncles, both grandfathers, 1 maternal 
uncle and 1 maternal aunt had unspecified cancers.
Other reports underscore the fact that transitional cell 
carcinoma of the upper urinary tract may represent a signif­
icant expression of hereditary nonpolyposis colon cancer,29- 35 
In the Japanese family reported on by Chiba et al the pro­
band was diagnosed with transitional cell carcinoma of the
renal pelvis a t age 49 years and she subsequently had endo­
metrial carcinoma a t age 50 years .33 The 3 brothers of this 
patient were diagnosed w ith colorectal cancer before age 45 
years. One brother subsequently had transitional cell carci­
noma of the left ureter a t age 49 years and multiple bladder 
tumors at age 51 years. One brother had adenocarcinoma of 
the stomach and transitional cell carcinoma of the renal 
pelvis a t age 45 years. Greenland et al reported on 4 male 
siblings with transitional cell carcinoma, 3 of whom had 
renal pelvis cancer.35 Two of the 4 siblings and 2 of their 
children had colorectal adenocarcinoma. A surprising detail 
in this report is th a t the family came to attention after the 
wrong set of records was produced for 1 case. Before that time 
neither the patients themselves nor the urologist who treated 
3 cases was aware of the familial clustering.
The risk of transitional cell carcinoma is also reported to be 
greater in families with the Muir-Torre syndrome, a rare 
autosomal dominant condition characterized by at least 1 
sebaceous tumor and at least 1 visceral malignancy (predom­
inantly proximal colon cancer). The clinical features of this 
syndrome can overlap with those of hereditary nonpolyposis 
colon cancer.36-37 Families w ith the Muir-Torre syndrome 
have an increased risk of upper and lower urinary tract 
transitional cell carcinoma, in  contrast to families with he­
reditary nonpolyposis colon cancer, in which there is no clear 
increased risk of bladder cancer,12’38*39
Another study suggests th a t familial transitional cell car­
cinoma of the upper urinary  tract can occur in other settings. 
Marchetto et al reported on a 48-year-old woman with trans­
itional cell carcinoma of the  ureter who had endometrial 
cancer 2 years later .40 Her mother had transitional cell car­
cinoma of the ureter and renal cell carcinoma at age 57 years, 
and bladder cancer 3 years later. A 69-year-old cousin of the 
mother had transitional cell carcinoma of the bladder and 
ureter, and she was diagnosed with endometrial cancer 1 
year previously. Four siblings of the mother had breast can­
cer, liver cancer, gastric adenocarcinoma and lung cancer. 
The maternal grandfather died of a brain tumor at age 42 
years. No colorectal tumors were identified in this pedigree.
Strong familial clustering of transitional cell carcinoma of 
the upper and lower urinary tract has also been found in 
some rural areas of the Balkan states of eastern Europe.41-43 
It is likely that the site specific familial clustering in these 
areas is related to Balkan endemic nephropathy and expo­
sure to environmental causes, such as ochratoxin A.44 The 
high risk of transitional cell carcinoma among consanguine­
ous married persons and the low risk among relatives who 
moved to nonendemic villages strongly argue against a ge­
netic origin.
EPIDEMIOLOGICAL STUDIES
Case-control studies. A variety of studies have examined 
familial clustering of bladder cancer (see table) ,10*45-64 Most 
studies were small and used an ill-defined definition of fam­
ily history. However, 3 studies will be highlighted for differ­
ent reasons. The largest study is a population based exami­
nation of 2,982 patients and 5,782 controls conducted in 1978 
(the United States national bladder cancer study) .51 Of the 
cases 6% versus 4% of the controls identified at least 1 
member in the immediate family (that is parents and sib­
lings) who had genitourinary cancer. The odds ratio adjusted 
for race, sex, smoking and age was 1.5 (95% confidence in­
terval 1 .2  to 1 .8 ), which can be interpreted as a 50% greater 
risk of bladder cancer if there is a first degree relative with 
cancer of the genitourinary tract. This risk appeared to be 
somewhat greater in persons younger than 45 years (odds 
ratio 2.7, 95% confidence interval 0.8 to 2.9) and in female 
patients (odds ratio 1.8, 95% confidence interval 1.1 to 2.7). 
Unfortunately, examination of family history was not a major 
objective of this study. Therefore, the authors were unable to
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Case-coiitrol studies o f transitional cell carcinoma in which fam ily  history was evaluated
Reference (country) Disease (No, pts.) No. Controls Exposure Measurement
%
Prevalence 
in Controls
Odds
Ratio
Adjustment
for
Smoking
Comment
Morganti et al 
(Italy)45
Wynder et al (United 
States)46 
Miller et al 
(Canada)47 
Cartwright (United 
Kingdom)48
Sullivan (United 
States)49 
Najem et al (United 
States)50 
Kantor et al (United 
States)51
Piper et al (United 
States)62
Bravo et al 
(Spain)53
Ross et al (United 
States)10
You et al (China)64
Akdas et al 
(Turkey)55
Kunze et al 
(Germany)66
Bladder Ca (160) 160 Hospital
Bladder Ca(370) 370 Hospital 
Bladder Ca (264) 528 Hospital
Bladder Ca Hospital
Bladder Ca in men of 
first and second de­
gree
“Family history” (ill- 
defined)
Family history of Ca
Bladder Ca in first and 
second degree rela­
tives
Bladder Ca (82)
Prevalent blad­
der Ca (75) 
Bladder Ca 
(2,900)
Bladder Ca (162 
women 20-49 
yrs. old) 
Bladder Ca (406)
169 Population Family history of uri­
nary Ca
142 Hospital Family history of Ca
5,684 Population Ca of urinary tract in
parents or siblings
162 Population
406 Hospital
Bladder/kidney Ca in 
first degree relatives
Family history of Ca
Renal pelvis 
and/or ureter
Ca (187) 
Bladder Ca (317)
187 Neighbor* 
hood
317 Hospital
Bladder Ca (194) 194 Hospital
Family history of kid­
ney/bladder Ca
Family history of blad­
der/other Ca
Family history
Benign and ma­
lignant tumors 
of urinary tract 
(675)
675 Hospital Bladder Ca in first de­
gree relatives
1.2
32
3.8
0.6
0/3.7
?/?
?
2.0
1.0
1.35
1.5»
4.0
oo*/o,6
1.29/1.66
2.5 Men*/
1.5 women
No
No
•?
Yes
No
Yes
Yes/No
No
Yes
Brief report
No correlation with blad­
der Ca 
Retrospective study
Total study population 
1,261, total prevalence 
7.6%, preliminary re ­
port, final results never 
published 
Nonsignificant higher fre­
quency among cases 
No statistically signifi­
cant difference 
Higher risk in younger 
pts., women and smok­
ers
Of 5 pos. answers 3 con­
cern kidney Ca
Family history improved 
the multivariate model 
(but significance level 
unknown)
Brief description of the 
methods makes inter­
pretation difficult 
Family history had no 
impact on the risk of 
bladder Ca
Not listed in the table are studies in which questions were asked about family history of bladder cancer but that did not yet supply results (possibly indicating 
negative findings), including studies from Denmark,57'58 Canada,69,60 Italy,61 China,82 and Iowa.63 Another study with positive results on family history was 
reported in the Russian literature only,64
* Statistically significant.
distinguish bladder cancer from kidney cancer, for example, 
and were not able to verify reports of familial cancer. A later 
study acknowledged that family history was not clearly as­
sociated with tumor stage and grade at diagnosis.65
Piper et al performed a case-control study in young women, 
the group with a greater than average odds ratio for family 
history in the aforementioned United States national bladder 
cancer study .52 A total of 162 women with bladder cancer 2 0  
to 49 years old was matched to population controls and asked 
about the history of bladder or kidney cancer (renal cell and 
transitional cell carcinoma) in first degree relatives. Four 
patients (2 .5 %) and 1 control subject (0 .6 %) reported a posi­
tive family history, yielding an insignificant odds ratio of 4.0. 
Only 1 individual reported bladder cancer in a parent, and 1 
reported tha t a sister had papillary cancer of the kidney and 
ureter. The remaining 2 patients and 1 control subject re­
ported kidney cancer in the father. Thus, there is a striking 
difference between the prevalence of a positive history in 
this study and th a t in the United States national bladder 
cancer study. Of course, young women usually have young 
relatives with a low risk of bladder cancer. However, in the 
national bladder cancer study the prevalence was also much 
greater among female controls only (3.3%) and among con­
trols younger than 45 years (2.0%). The reason for this dif­
ference remains unknown.
In a German study conducted by Kunze et al 675 cases of 
histologically confirmed benign or malignant epithelial tu ­
mors of the bladder, ureters, renal pelves and urethra were 
compared to matched controls with nonneoplastic diseases of 
the lower urinary tract (predominantly prostatic hyperplasia
in men and urinary tract infection in women) .56 An in ter­
viewer administered questionnaire noted bladder cancer in 
first degree relatives. In a multivariate analysis, controlling 
for smoking status, occupational exposures and phenacetin 
use, a positive family history showed an odds ratio of 2.5 
(95% confidence interval 1.1 to 5.8) in men and a statistically 
insignificant odds ratio of 1.5 in women. This greater risk in 
men is in contrast with the findings from the United States 
national bladder cancer study .52
Other epidemiological studies. A disadvantage of the afore­
mentioned case-control studies is th a t the exposure (bladder 
cancer in the family) was examined by simple questions 
asked the patients and controls. No adjustment could be 
made for total number of relatives, age, sex, smoking status 
and age of the relatives at cancer diagnosis. However, 1 study 
specifically addressed the issue of familial bladder cancer, 
and collected demographic data and cigarette smoking status 
on all first degree relatives of 319 men with bladder cancer 
diagnosed in New York State and 319 neighborhood con­
trols.66 The 2  cohorts of relatives were then linked to the New 
York State Tumor Registry to obtain valid data on cancer 
occurrence. A total of 14 cases of bladder cancer was found 
among 1,619 relatives of patients and 7 were found among 
1,773 relatives of controls, In a multivariate proportional 
hazards regression model with age, sex and smoking status, 
the hazard ratio of case-control status was 1.9 (90% confi­
dence interval 0.9 to 4.1). According to the authors, there 
were no instances in which more than 1 first degree relative 
within a family was affected. Thus, the prevalence of a pos­
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itive family history among the controls can be estimated at 
2 .2 %.
In a small hospital based study by Lynch et al the cumu­
lative risk of bladder cancer among first and second degree 
relatives of 49 consecutively ascertained bladder cancer cases 
was compared to the expected risk based on the United 
States third national cancer survey,67 The cumulative risk 
among relatives of the patients was 1.63 times greater than 
expected. The same comparison was made for the relatives of
3 other cancer groups (254 patients with lung cancer, 138 
with other smoking related cancers and 564 with nonsmok­
ing related cancers). The risk for the relatives of these pa­
tients was not increased. This finding supports a nonenvi- 
ronmental cause of familial clustering. In an additional 
analysis the authors found significant heterogeneity of risk 
across families, and only 3 of the 49 families studied (6 %) 
were at high risk. In contrast, in a study of Danish twins no 
differences were found between the concordance rate  of uri­
nary system cancers in 1,528 monozygotic twin pairs and in 
2,609 same sexed, dizygotic twin pairs ,68 In fact, in neither 
group was a pair with both twins affected found. This result 
has been used as an argument against a hereditary subtype 
of bladder cancer. However, the concordance rates of breast 
cancer and intestinal tumors (for which hereditary forms are 
known to exist) were also not greater in monozygotic twins.
Skolnick et al,69 and Bishop and Skolnick70 presented the 
mean kinship coefficients of Mormon descendants registered 
in the Utah population based cancer registry. The kinship 
coefficient, which expresses the probability th a t randomly 
selected homologous genes from 2  individuals are identical by 
descent, was calculated by using the genealogy data base of 
the Utah Mormons.71 They found tha t lip cancer, melanoma 
and skin cancer had the highest mean kinship coefficient, 
followed by ovarian, prostate, colon, breast, rectum and blad­
der cancer. Mean kinship coefficient for bladder cancer was 
2.07 X 10 “5, which was only slightly lower than that for early 
onset (younger than 50 years) breast cancer (kinship coeffi­
cient 2.23 X 10-5). In comparison, mean kinship coefficient 
for all cancer sites combined was 1.76 X 10” 5 and tha t for a 
random sample of 3,000 U tah Mormons was 1.40 X 10“ 5, 
which supports familial clustering of bladder cancer. How­
ever, the methodology is indirect and has many caveats. For 
example, mean kinship coefficient does not distinguish be­
tween genetic and environmental causes of familiality. Fur­
thermore, a fairly large mean kinship coefficient may origi­
nate from only 1 or a few related individuals (for example 1 
pair of siblings among 150 further unrelated bladder cancer 
patients would result in a kinship coefficient of 2.25 X 10”5). 
A later article on the same study population reported that 
familiality of bladder cancer was greater among the youngest 
(less than 6 6  years old) and among female patients .72
Future studies, Analysis of currently available data on 
familial transitional cell carcinoma is flawed by incomplete 
data collection, and the complexity inherent in performing 
epidemiological studies on diseases tha t purportedly result 
from multifactorial ideologies. In an attempt to address the 
issue of familial transitional cell carcinoma, a study to con­
firm hereditary transitional cell carcinoma is about to begin 
in The Netherlands that will address issues, such as extent of 
transitional cell carcinoma clustering in families, extent to 
which this clustering is determined by hereditary factors, 
mode of inheritance of familial transitional cell carcinomas 
and whether common karyotypic abnormalities exist in trans­
itional cell carcinoma families. In a recent study a family was 
identified in which the proband had germline translocation of 
the short arm of chromosome 5 to the long arm of chromo­
some 20.73 Other members of the family had melanoma and 
transitional cell carcinoma, raising the possibility that this 
translocation may provide additional information about the 
genetic underpinnings of familial transmission of bladder 
cancer. A population based case-control study will be con­
ducted in The Netherlands beginning in 1996 in which 1,000 
cases of newly diagnosed transitional cell carcinoma of the 
bladder, ureter and renal pelvis will be selected from na­
tional cancer registries. A detailed family history of cancer in 
first and second degree relatives will be collected from the 
patients and spouses via a postal questionnaire. Smoking 
behavior and occupational exposure will be evaluated. For­
mal cluster and segregation analyses, as well as karyotypic 
analyses will be performed.
CONCLUSIONS
It is a well accepted fact that transitional cell carcinoma 
may cluster in certain cancer family syndromes, such as the 
Lynch type II (particularly ureter and renal pelvis tumors) 
and Muir-Torre (lower and upper urinary tract tumors) syn­
dromes. A large number of case reports suggest th a t familial 
transitional cell carcinoma also exists as a unique entity 
despite the fact th a t it is difficult to draw firm conclusions 
from such reports. The causes of this familial clustering as 
well as its frequency are subject to speculation but a contrib­
uting genetic cause is likely considering the early age at 
onset of disease in some families in the literature. The pat­
tern of occurrence is consistent with autosomal dominant 
inheritance of a major cancer predisposing gene that has 
decreased penetrance. Except for an early age at disease 
onset, and possibly clustering with other types of tumors, the 
case reports do not provide any clear indication about poten­
tial characteristics of familial transitional cell carcinoma (for 
example multiplicity, stage of disease and prognosis).
Evidence for familial transitional cell carcinoma from epi­
demiological studies is inconclusive. Studies with small sam­
ple sizes and those using an indirect approach to evaluate 
familiality suggest a weak or even absent familial clustering. 
Large case-control studies, as well as the only study that 
specifically addresses the issue of familial bladder cancer 
suggest a familial form of transitional cell carcinoma.66
Study of hereditary forms of cancers has yielded important 
clues about the etiology and pathogenesis of sporadic forms of 
these tumors. For example, the adenomatous polyposis coli 
gene is mutated in almost all colon cancers but was first 
mapped in pedigrees with familial adenomatous polyposis. 
Furthermore, knowledge of germline mutations may direct 
early detection of cancer, as is the case in hereditary non­
polyposis colon cancer and hereditary breast cancer. There­
fore, it would seem important to confirm the existence of a 
familial subtype of transitional cell carcinoma, and to search 
for evidence tha t such familial clustering may be caused by 
specific genes.
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